Zanwar, S., Pasvolsky, O., Hansen, D., Goel, U., Afrough, A., Rana, M., Portuguese, A., Davis, J., Sborov, D., Bal, S., Janakiram, M., Shune, L., Ferreri, C., Biran, N., Herr, M., Hassan, H., Grajales-Cruz, A., Khouri, J., Corraes, A. D. M. S., Kort, J., Atrash, S., Puglianini, O., Baz, R., Cassano, R. C., Liang, E., Zolotov, E., Ali, H. M., Varga, C., Richards, T., Hosoya, H., Gaballa, M., Dillard, C., Fortuna, G. G., Lee, L., Julian, K., Green, K., Sannareddy, A., Anderson, L., Alsina, M., Raza, S., Dima, D., Mikkilineni, L., Anwer, F., Banerjee, R., Krishnan, A., Locke, F., Voorhees, P., Kumar, S., Sidana, S., Patel, K., Dhakal, B., Lin, Y., Costa, L. (2025). Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations. Blood. https://doi.org/10.1182/blood-2025-4069